Syniad’s Gemina Labs Appoints Dr. Michael Shannon as Chair of Clinical Advisory Board 

December 20, 2022, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the “Company” or “Gemina”) is delighted to announce Dr. Michael Shannon has been appointed to constitute and Chair the Company’s Clinical Advisory Board.

Dr. Shannon is one of Canada’s pre-eminent public health leaders. He spent 31 years in the Canadian Forces, retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Subsequently, he was appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years. Later he served as an Audit Principal and Senior Medical Advisor to the Canadian Auditor General and then accepted responsibilities for rebuilding the Emergency Medical Response System within the newly formed Public Health Agency of Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was successfully conducted in Toronto.

Outside of public service, Dr. Shannon has been an advisor to numerous life science companies in both therapeutic and other bioscience applications. His formal training includes a medical degree from Queen’s University and post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for 30 years.

Dr. Shannon stated, “I am delighted to work with Gemina at this stage of its development. The past three years have demonstrated the utility of point-of-care testing in public health, primary care and home settings. The Gemina team has a compelling plan to develop a portfolio of accurate and reliable tests with improved ease of use. I look forward to building an active clinical advisory board that will provide Gemina with insights and knowledge important for the success of its products and technologies.”

Brian Firth commented, “Gemina’s product development trajectory has reached a stage where it’s important to establish a clinical advisory board, to ensure that the Company is positioned to make the best possible decisions when it comes to its product-market choices. We’re incredibly pleased to be able to welcome Dr. Shannon to the Company. He is an immensely distinguished practitioner with extraordinary insight into both national and international public health concerns, including global threats to public health such as COVID-19. I’m looking forward to working with him to build Gemina’s Clinical Advisory Board in the weeks and months to come.”

Learn more at: https://www.geminalabs.com/

Syniad Innovations is a company focused on building breakthrough deep tech companies around cutting-edge advances in science & engineering, like quantum networking.

Syniad addresses some of the world’s most pressing challenges by collaborating with exceptional researchers and provides the expertise, capital, and networks to help accelerate their ideas into important new products and services. Founded in 2015 in Vancouver, Syniad possesses a unique pedigree in research commercialization.

Our experience includes projects with various stakeholders, from Fortune 500 companies to governments and universities that want a step change in impact.